Liposomal amphotericin B: clinical experience and perspectives

Area of Science:

• Mycology
• Infectious Diseases
• Pharmacology

Background:

• Amphotericin B deoxycholate has been a long-standing treatment for invasive fungal infections.
• Significant toxicities limit amphotericin B deoxycholate use, prompting development of safer alternatives.
• Lipid-based formulations, such as liposomal amphotericin B, aim to mitigate these toxicities.

Purpose of the Study:

• To review recent clinical experience with liposomal amphotericin B.
• To compare liposomal amphotericin B efficacy and safety against amphotericin B deoxycholate and other antifungals.
• To assess the pharmacoeconomic implications of liposomal amphotericin B use.

Main Methods:

• Review of clinical trials and pharmacoeconomic analyses.
• Comparison of efficacy, toxicity profiles, and acquisition costs.
• Evaluation of treatment-related outcomes and costs.

Main Results:

• Liposomal amphotericin B demonstrates comparable efficacy to amphotericin B deoxycholate.
• Liposomal amphotericin B shows a reduced incidence of nephrotoxicity, electrolyte wasting, and infusion reactions.
• Acquisition costs for liposomal amphotericin B are significantly higher; cost-effectiveness remains unclear.

Conclusions:

• Liposomal amphotericin B provides a safer alternative to amphotericin B deoxycholate for invasive fungal infections.
• Further pharmacoeconomic studies are needed to establish the overall cost-effectiveness of liposomal amphotericin B.
• Liposomal amphotericin B represents an important option in managing invasive fungal infections, balancing efficacy and safety.